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Abstract
Background: It is undetermined whether calcium supplementation has an effect on obesity or body composition
in postmenopausal women. The purpose of the study is to detect the effect of calcium supplementation on
indices of obesity and body composition.
Methods: This is a secondary analysis of data from a population-based, double-blind, placebo-controlled,
randomized trial designed to determine the effects of calcium and vitamin D on osteoporotic fractures. The cohort
included 1179 postmenopausal women who were randomly assigned into one of three groups: 1) supplemental
calcium (1400 mg/d or 1500 mg/d) plus vitamin D placebo (Ca-only group); 2) supplemental calcium (1400 mg/d
or 1500 mg/d) plus supplemental vitamin D3 (1100 IU/d) (Ca + D group); or, 3) two placebos (placebo group).
After applying the exclusion criteria for this analysis, 870 subjects were included in this study. The primary
outcomes for the present study were changes in body mass index, trunk fat, trunk lean, and percentage of trunk
fat after calcium supplementation.
Results: Changes in trunk fat, trunk lean, and percentage of trunk fat were significantly different between the
calcium intervention groups (Ca-only group or Ca + D group) and the placebo group during the trial (P < 0.05).
The calcium intervention groups gained less trunk fat and maintained more trunk lean when compared to the
placebo group. No significant difference was observed for body mass index between groups.
Conclusion: Calcium supplementation over four years has a beneficial effect on body composition in
postmenopausal women.
Background
An urgent need exists to identify modifiable dietary risk
factors for obesity. Obesity has become a major health
threat around the world. It is epidemic, and the risk
increases with age [1-3]. In fact, it is estimated that
~ 7 0 %o fA m e r i c a n so v e r6 0y e a r sa r eo v e r w e i g h t[ 4 ] .
Women are more prone to the risk of obesity than men
[3]. Elderly women who have excess body fat accumula-
tion face increased risk for coronary heart disease,
hypertension, metabolic syndrome, osteoarthritis,
diabetes mellitus, and other co-morbidities [5-10].
A body of evidence has emerged to support the
hypothesis that dietary calcium plays a role in decreas-
ing the risk of obesity. Cross-sectional studies have
shown that calcium intake has a negative correlation
with body weight, body mass index (BMI), body fat, and
percentage of body fat [11-16]. For example, in the
NHANES III survey [17], the odds ratio of being in the
highest quartile of body fat was significantly lower if
individuals were in the highest quartile of calcium
intake. The relative risk of high body adiposity was
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intake and was progressively lower as calcium intake
increased.
Randomized placebo-controlled trials have provided
evidence that is supportive of the beneficial effect of
high calcium intake on obesity [18-21]. In these trials,
greater weight loss and/or fat mass loss were observed
in the high-dairy supplemented group compared to the
placebo group. Data from the Women’s Health Initiative
(WHI) Study has provided supportive evidence as well
[22]. In this randomized placebo-controlled trial, which
involved over 36000 postmenopausal women over an
average term of seven years, the calcium plus vitamin D
supplemented group experienced smaller weight gain
than the placebo group.
While the aforementioned clinical trials indicated a
beneficial effect of calcium, two systematic reviews
found no evidence of benefit from calcium supplementa-
tion on body weight loss [23,24]. Thus, the role of sup-
plemental calcium in preventing obesity remains
controversial.
It should be noted that the abovementioned clinical
trials were generally conducted in obese [18-20] and/or
low-calcium consumers [18-20,22], and that increased
dietary calcium was primarily in the form of dairy pro-
ducts [18-21]. In the WHI Study, the phenotype is total
body weight [22]. However, weight is a heterogeneous
phenotype consisting of fat, lean, and bone mass. There-
fore, the change in weight does not always reflect the
change in fat.
It is reported that serum 25-hydroxy vitamin D [25
(OH)D] is negatively associated with obesity status
[25-27]. That is, those subjects who have high serum 25
(OH)D levels generally have a lower risk of obesity.
However, the relationship between vitamin D intake and
obesity is yet undetermined [28,29].
Our population-based study of older women who have
aw i d er a n g eo fb o d ys i z ep r o v i d e da no p p o r t u n i t yt o
assess the effects of calcium, and calcium plus vitamin
D supplements on obesity in a large sample over a sus-
tained, four-year period of time. Moreover, this trial
included a variety of phenotypes by which to assess the
calcium and calcium plus vitamin D effects. Fat mass
and lean mass are more homogenous phenotypes in
comparison to body weight or BMI. Thus, these pheno-
types should be more sensitive to the possible beneficial
effects of calcium and calcium plus vitamin D.
Methods
Participants
1) The subjects for the 4-year clinical trial
The original cohort included 1179 non-Hispanic white
women who were randomly selected from a population
of postmenopausal women > 55 years of age in a
nine-county rural area of the Midwest. A full-service
market research firm randomly selected telephone num-
bers from all households with listed numbers in the
nine-county rural sample area. The firm identified 1180
women meeting the inclusion and exclusion criteria
who were willing to participate in a four-year prospec-
tive study of calcium and vitamin D supplementation.
The participants were enrolled into study between May
2000 and July 2001. The study was approved by the
Creighton University Institutional Review Board, and
signed informed consent was obtained from each parti-
cipant. The inclusion criteria for the 1180 subjects were:
1) at least four years since last menses; 2) in generally
good health; 3) living independently in the community;
and 4) weighing less than 300 pounds. Exclusion criteria
included: a history of cancer except for basal and squa-
mous cell skin cancers and other cancers treated cura-
tively over ten years prior to enrollment; history of renal
calculi or chronic kidney disease; and, a history of
Paget’s disease. One woman was excluded after entry,
when she disclosed a history of hypoparathyroidism fol-
lowing thyroidectomy and reported having taken 50000
IU of vitamin D daily for the past 25 years.
T h es u b j e c t sw e r er a n d o m l ya s s i g n e dt oo n eo ft h r e e
groups: 1) calcium, consisting of either calcium citrate
(1400 mg/d) or calcium carbonate (1500 mg/d) plus a
vitamin D placebo (defined as Ca-only group, 445 sub-
jects); Heaney et al. found that, when taken with food,
calcium from the carbonate salt is fully as absorbable as
from the citrate [30]; 2) calcium plus vitamin D, consist-
ing of calcium (as above) plus 1100 IU cholecalciferol
(vitamin D3)/d (defined as Ca + D group, 446 subjects);
and 3) placebos, consisting of both a vitamin D placebo
and a calcium placebo (defined as placebo group, 288
subjects). In the present study, calcium and vitamin D
placebo, calcium and vitamin D, or placebos only, were
taken three times daily, to be swallowed with meals.
Enrolled subjects were assigned to groups using
computer-generated permuted blocks (n = 5) randomi-
zation scheme. By design (initially for fracture), the two
active treatment groups (Ca only and Ca + D group)
were each allocated ≈40% (446 of 1180 participants) of
the cohort, and the placebo group, 20% (288 of 1180
participants). Of the 1180 women enrolled, 1024 (86.9%)
completed the 4-year study. Most withdrawals (n =9 2 )
occurred within the first year. Compliance with study
medication (both active and placebo) was assessed at
6-month intervals by bottle weight. The average compli-
ance rate (defined as taking ≥ 80% of assigned doses)
was 74.4% for the calcium component, and 85.7% for
the vitamin D component.
2) Subjects selected for the present study
In order to reduce confounding effects, we established
three exclusion criteria for selecting subjects for this
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were excluded. Metal prostheses/implants interfere with
the accuracy of a DXA in assessing trunk fat mass, the
main phenotype in the study. In addition, subjects with
cancer were excluded. It is well established that cancer
patients usually lose weight [31]. Therefore, application
of the cancer exclusion criterion is designed to minimize
the influence of the disease on weight-related pheno-
types. All subjects who did not complete the 4-year clin-
ical trial were excluded. Among the 155 non-completing
subjects, most of the drop-off (n = 128) occurred within
the first two years. Because the beneficial effect of cal-
cium on obesity is slow and is not evident in the initial
two years, excluding any subjects who did not complete
the study is reasonable. After applying the exclusion cri-
teria, we retained 870 qualified subjects. Table 1 lists
the number of subjects excluded after applying each
exclusion criterion. For the selected 870 subjects, the
average calcium compliance rate was 76.0%; the vitamin
D compliance rate was 86.9%.
Phenotypes, biomarker and confounding factors
Phenotypes and biomarkers were measured at baseline
(defined as the initial visit before calcium and/or vitamin
D intervention), then measured yearly during the 4-year
trial (defined as years 1-4). The phenotypes included
BMI, trunk fat (TrF), trunk lean (TrL), and percentage
of trunk fat (PTrF). Weight and height were measured
with subjects’ shoes, coats, and other heavy outerwear
removed. BMI is calculated by taking a person’sw e i g h t
and dividing by their height squared. TrF and TrL were
measured by dual energy x-ray absorptiometry (DXA)
using a Hologic 4500C scanner upgraded to a 4500W
running software version 8.26 (Hologic Inc., Bedford,
MA, USA). The DXA was calibrated each day of analy-
sis, and the margin of error was maintained within 1.5%.
Changes in BMI, TrF, TrL, and PTrF (ΔBMI, ΔTrF,
ΔTrL, and ΔPTrF) were calculated as the primary
outcomes in the present study.
Serum 25-hydroxyvitamin D [25(OH)D] was measured
annually. Serum samples for 25(OH)D measurement
were collected after a 3-hour fast. Participants were asked
not to take vitamin or mineral supplements that
morning. Serum 25(OH)D was measured by radioimmu-
noassay (Nichols/Quest Diagnostics, San Clemente, CA).
The coefficient of variation (CV) for intra-assay was 5.1%
and inter-assay was 7.9%. All analyses were completed in
a single laboratory that participates in the Quality
Assurance Program for Vitamin D (DEQAS) [32].
Height, smoking status, and estrogen usage were deter-
mined. Age was recorded accurately to one day. Because
obesity status may be affected by season, we divided a
year into three seasons: a hot season (Jun.-Aug.), a warm/
cool season (Mar.-May, Sep.-Nov.), and a cold season
(Dec.-Feb.). Smoking status was quantitatively measured
as pack-year (amounts previously and currently smoked),
and was qualitatively recorded as “never,”“ former” or
“current” smoker. Estrogen usage was recorded as
“never,”“ less than 6 months” and “more than 6 months”
of usage.
The total calcium intake included dietary calcium
(from food), habitual calcium supplement, and the trial
calcium supplementation. Habitual calcium supplemen-
tation is defined as “self-selected supplementation that a
subject takes during the trial.” Trial calcium supplemen-
tation was calculated using an assigned dose (1400 mg/d
or 1500 mg/d) multiplied by the subject’sc o m p l i a n c e
rate. Calcium compliance rate was measured at 6-month
intervals. However, the dietary calcium and habitual cal-
cium supplementation was measured only at baseline
visit and at the final visit. To achieve consistent mea-
surements, an average calcium compliance rate was
used for calculating the trial calcium intake. The average
compliance rate was calculated using all available
records during the 4-year trial. Similar to calcium
intake, total vitamin D supplementation was measured
as a combination of habitual vitamin D supplementation
and trial vitamin D supplementation.
Statistical analysis
Data were analyzed with SPSS for Windows, Release
16.0 (SPSS Inc, Chicago, IL). All tests were two-sided
and P < 0.05 was considered as significant.
Descriptive statistics and analyses of variance
(ANOVA) were performed for confounding factors and
phenotypes at baseline. For the follow-up phenotype
changes, a Pearson correlation and a stepwise multiple
regression were conducted to detect significant con-
founding factors for each phenotype at each follow-up
measure (time point). For the primary analysis, we used
an analysis of covariance (ANCOVA) to model the
Table 1 Subjects selected for the project
Groups Placebo Ca-
only
Ca +
D
Total P
Initial subjects 288 445 446 1179
Exclusion Not finished 44 54 58 155 0.46
Metal prostheses/
implants
36 60 52 148 0.71
Cancer 20 17 13 50 0.03
Total excluded subjects 82 117 110 309 0.52
Applied subjects 206 328 336 870 0.52
Note: There were some overlaps between different exclusion criteria.
Not finished: subjects who did not finished the 4-year trial; Metal prostheses/
implants: subjects with prosthetics or pacemakers implants; Cancer: subjects
suffering from cancer during the 4-year trial.
P values were calculated by c
2 test to compare the difference of ineligible
subjects among the three groups.
Zhou et al. Nutrition & Metabolism 2010, 7:62
http://www.nutritionandmetabolism.com/content/7/1/62
Page 3 of 9effect of treatment on phenotype changes with signifi-
cant confounding factors as covariates at each follow-up
measure. Independent-sample t-tests applying the Bon-
ferroni correction were performed when the differences
between groups were significant. The same analyses
were conducted for serum 25(OH)D. In addition to
ANCOVA, repeated measures analyses using pooled
measures were conducted. In the data analyses, treat-
ment, age, season, estrogen use, and their interactions
were included in the model.
For both baseline phenotypes and follow-up pheno-
type changes, Pearson correlation or Spearman correla-
tion analyses were conducted against various sources of
calcium intake and vitamin D supplementation. The
same analysis was completed for the baseline serum
25(OH)D.
Results
Characteristics of the study subjects
Table 1 summarizes the subjects selected for the study.
The initial participants have been described in detail in
one of our articles describing their vitamin D status
[33]. The following subjects were excluded: 155 subjects
who did not finish the study, 148 subjects who had
metal prostheses/implants that may affect the accuracy
of phenotype measurement, and 50 subjects who were
diagnosed with cancer during the study. After applying
the exclusion criteria, 870 total subjects were selected
for the proposed study. The differences of excluded sub-
jects among the three groups were compared using c
2
test. The P values are listed in the Table 1. The
excluded subjects among the three groups are not differ-
ent for any of the tested phenotypes, except for the inci-
dence of cancer.
Table 2 details the basic characteristics of the 870 sub-
jects at baseline. For all baseline characteristics, no sig-
nificant differences among the three groups emerged. At
baseline, the average age of all subjects was 66.0 ± 6.9 y,
and average BMI was 28.8 ± 5.3 kg/m
2. The average 25
(OH)D at baseline was 73.2 ± 19.9 nmol/L. The mean
total calcium intake of the three groups was 1016 ± 520
mg/d and the mean habitual vitamin D supplementation
was 198 ± 189 IU/d.
Test the effects of calcium and calcium plus vitamin D on
phenotype changes during the trial
Baseline obesity-related phenotypes are important
factors affecting the 4-year obesity status. The effect of
calcium intake on obesity-related phenotypes is moder-
ate. In order to reduce the baseline effect and amplify
the change of phenotypes, %change is used in Figures 1
and 2. To estimate the absolute change value, this value
can be achieved easily by multiplying the percentage
change with the basic value in Table 2.
Figure 1 shows the timeline of phenotype changes in
the three groups during the 4-year intervention. Analysis
of covariance (ANCOVA) was used to test the differ-
ences in the three groups. The P value is presented in
Figure 1 for each year of the study. For ΔBMI, the
change trend is different among the three groups, even
though significant differences were not observed among
the three groups. After 4 years of calcium and vitamin
D intervention, the BMI decreased in the Ca + D group,
increased in the placebo group, and remained approxi-
mately unchanged in the Ca-only group. The weight
change is consistent with that of the ΔBMI (data not
shown).
Although we did not observe a significant difference
among the three groups for ΔBMI, evidence of signifi-
cant difference was found when we used ΔTrF, ΔPTrF,
and ΔT r L .W en o t e dt h a tt h ec h a n g e si nT r Fa n dT r L
trended in opposite directions. After four years of cal-
cium and vitamin D intervention, subjects from all the
three groups gained TrF and lost TrL, although the
rates of gain and loss are different between groups. For
ΔTrF and ΔP T r F ,t h eC a - o n l ya n dt h eC a+Dg r o u p s
Table 2 Descriptive characteristics (Mean ± SD) for the selected 870 subjects at baseline
Variables Total
n = 870
Placebo
n = 206
Ca-only
n = 328
Ca + D
n = 336
P
Age (y) 66.0 ± 6.9 65.2 ± 6.5 66.0 ± 6.6 66.5 ± 7.5 0.13
Body mass index (kg/m
2) 28.8 ± 5.3 28.8 ± 5.3 28.9 ± 5.4 28.7 ± 5.2 0.96
Trunk fat (kg) 14.3 ± 4.7 14.3 ± 4.8 14.5 ± 4.8 14.1 ± 4.6 0.53
Trunk lean (kg) 21.9 ± 3.1 22.1 ± 2.9 22.0 ± 3.2 21.8 ± 3.1 0.37
Percentage of trunk fat (%) 38.6 ± 6.5 38.3 ± 6.6 38.9 ± 6.8 38.5 ± 6.1 0.55
25(OH)D (nmol/L) 73.2 ± 19.9 73.6 ± 20.7 73.0 ± 20.4 73.1 ± 18.8 0.93
Dietary calcium intake (mg/d) 670 ± 389 671 ± 406 681 ± 376 658 ± 392 0.74
Habitual calcium supplement (mg/d) 347 ± 342 334 ± 318 342 ± 354 359 ± 345 0.68
Total calcium intake (mg/d) 1016 ± 520 1004 ± 518 1023 ± 508 1016 ± 535 0.92
Habitual vitamin D supplement (IU/d) 198 ± 189 189 ± 194 206 ± 186 196 ± 188 0.57
Note: P values were calculated by analysis of variance (ANOVA) to compare the means of variables among the placebo, Ca-only, and Ca + D groups.
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(mean 2.4%, 1.4% vs. 5.4%, P = 0.015 at year 3), and the
effect is more evident for ΔPTrF (mean 1.1%, 0.3% vs.
3.6%, P = 0.001 for year 3; and mean 1.8%, 2.0% vs.
4.9%, P = 0.003 at year 4). For ΔTrL, Ca-only and Ca +
D groups preserve more TrL than the placebo group,
and the effect became significant in year four (mean
-0.6%, -1.0% vs. -2.1%, P = 0.004 at year 4). The results
suggest that an increase in calcium intake tends to mod-
ify body composition by gaining less TrF and preserving
more TrL.
In the study, significant differences were not detected
between the Ca-only group and the Ca + D group for
any studied phenotypes (Figure 1). This suggests that, in
the study cohort, vitamin D supplementation provides
no additional beneficial effect on body composition. The
correlation analysis provided supportive evidence for
this finding. When considering habitual vitamin D
supplementation, trial vitamin D supplementation, and
total vitamin D supplementation amount, none of them
are associated with any changes in the tested phenotypes
(Table 3).
After excluding subjects with low adherence (< 80%)
of calcium intake, high calcium intake groups still have
significantly higher TrL and lower TrF, when compared
to the placebo group.
Figure 2 presents the serum 25(OH)D changes in the
three groups after calcium and vitamin D intervention.
P=0.10
P=0.28
P=0.39
P=0.45
P=0.12
P=0.18
P=0.03
P=0.06
Placebo
Ca-only
Ca +       D
Placebo
Ca-only
Ca +    D
P=0.26
P=0.05
P=0.001
P=0.003
P=0.28
P=0.12
P=0.09
P=0.004
Placebo
Ca-only
Ca +   D
Placebo
Ca-only
Ca +   D
Figure 1 Percentage changes (Mean ± SE) in body composition by group assignment over the 4 years. BMI: body mass index, TrF: trunk
fat, TrL: trunk lean, PTrF: percentage of trunk fat. Δ: percentage change, equals (Follow-up - Baseline)/Baseline * 100. Ca-only: calcium group; Ca
+ D: calcium plus vitamin D group; Placebo: placebos group. At baseline (year 0): Placebo (n = 206), Ca-only (n = 328), Ca + D (n = 336); at year
1: Placebo (n = 191), Ca-only (n=310), Ca + D (n=310); at year 2: Placebo (n = 187), Ca-only (n = 300), Ca + D (n = 298); at year 3: Placebo (n
= 189), Ca-only (n = 287), Ca + D (n = 296); at year 4: Placebo (n = 178), Ca-only (n = 274), Ca + D (n = 297). The P values were calculated by
analysis of covariance (ANCOVA) at each follow-up measure (time point). A general linear model (GLM) was used with phenotype changes as
dependent variables, treatment as an independent variable, age, season, and estrogen use (stepwise multiple regression P < 0.05) as covariates.
The significant covariates in the model were as follows: at year 1: season; at year 2: age, season, and estrogen use; at years 3 and 4: age and
estrogen use.
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jects in the Ca + D group had a significant increase in
serum 25(OH)D, while the placebo and Ca-only groups
remained stable (P < 0.001).
We conducted repeated measures analyses that
included phenotype measurement time (named as time
thereafter), treatment group (named as treatment there-
after), age, season, estrogen usage (named as estrogen
thereafter), and their interactions in the model. The
results from repeated measures analyses were consistent
with those from ANCOVA. For BMI, estrogen and
time*age were significant, and the P value for treatment
was 0.13. For TrF, treatment, age, estrogen, time*treat-
ment, time*age, time*season, and time*estrogen were
significant, and the P value for treatment was 0.007. For
TrL, treatment, season, and time*season were signifi-
cant, and the P value for treatment was 0.01. For PTrF,
treatment, age, season, time*treatment, time*age,
time*season, and time*estrogen were significant, and the
P value for treatment was less than 0.001. For 25(OH)D,
treatment, season, time*treatment, and time*season
were significant, and the P value for treatment was less
than 0.001.
Correlations between different types of calcium and
vitamin D consumption and baseline phenotypes and
year-4 phenotype changes
Results from Figure 1 indicate that calcium supplemen-
tation lowers TrF and increases TrL following long-term
intervention (three or four years), ultimately modifying
body composition. In order to test which type of cal-
cium intake contributes the most beneficial effect, corre-
lations between the amounts of different types of
calcium intake and phenotypes were tested at baseline
(n = 870) (Table 4). At baseline, dietary calcium is not
associated with any of the phenotypes (P > 0.05). Habi-
tual calcium supplementation was negatively associated
with BMI, TrF, TrL, and PTrF (P < 0.01). Compared
with habitual calcium supplement, total calcium intake
had a similar, but weaker, association with all the phe-
notypes (P < 0.01). Table 3 presents the correlation
coefficients between the amount of each type of calcium
intake and phenotype changes at the end of the study
(year 4). Trial calcium supplementation is inversely cor-
related with ΔTrF and ΔPTrF, and positively correlated
with ΔTrL. This result supports the ANCOVA results
presented in Figure 1.
Serum 25(OH)D was negatively associated with all the
phenotypes at baseline (BMI, TrF, TrL, and PTrF, Table
4). Consistently, Δ25(OH)D is inversely correlated with
ΔBMI, ΔTrF and ΔPTrF (Table 3). At baseline, habitual
vitamin D supplementation levels are associated with
TrF and PTrF. The correlation coefficients between
habitual vitamin D supplementation and TrF and PTrF
are relatively modest when compared to those between
serum 25(OH)D and TrF and PTrF.
Placebo
Ca-only
Ca +     D
P<0.001 P<0.001 P<0.001
P<0.001
Figure 2 Percentage changes (Mean ± SE) in serum 25(OH)D
by group assignment over the 4 years. The sample and the data
analysis method are the same as Figure 1.
Table 3 Correlation coefficients between calcium and
phenotype changes at year 4 (n = 749)
ΔBMI ΔTrF ΔTrL ΔPTrF
Calcium Dietary Ca Intake 0.012 0.007 0.047 -0.002
Habitual Ca Suppl. 0.053 0.055 0.010 0.058
Trial Ca Suppl. -0.037 -0.092* 0.127** -0.129**
Total Ca Intake 0.008 -0.034 0.118** -0.063
Vitamin D Habitual Vit D Suppl. 0.038 0.060 0.036 0.054
Trial Vit D Suppl. -0.066 -0.055 0.008 -0.057
Total Vit D Suppl. -0.036 -0.008 0.029 -0.016
Δ25(OH)D -0.147** -0.146** -0.032 -0.130**
Note: *: P < 0.05; **: P <0 . 0 1 .
Δ: percentage change, equals (Follow-up - Baseline)/Baseline * 100.
BMI: body mass index; TrF: percentage change in trunk fat; TrL: percentage
change in trunk lean; PTrF: percentage change in percentage of trunk fat.
Correlation coefficients were calculated by Pearson correlation, using pooled
data from the placebo, Ca-only, and Ca + D groups.
Table 4 Correlation coefficients between calcium, vitamin
D and obesity-related phenotypes at baseline (n = 870)
BMI TrF TrL PTrF
Calcium Dietary Ca Intake -0.054 -0.054 -0.016 -0.065
Habitual Ca Suppl. -0.120** -0.146** -0.085* -0.146**
Total Ca Intake -0.119** -0.136** -0.068* -0.145**
Vitamin D Habitual Vit D Suppl. -0.065 -0.071* -0.029 -0.093**
Serum 25(OH)D -0.260** -0.294** -0.179** -0.281**
Note: *: P < 0.05; **: P <0 . 0 1 .
BMI: body mass index; TrF: trunk fat; TrL: trunk lean; PTrF: percentage of trunk
fat.
In the data analysis, the selected subjects in Table 1 were pooled together at
baseline. Correlation coefficients were calculated by Pearson correlation.
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To the best of our knowledge, this is the first clinical
trial in a population-based postmenopausal women
cohort, to observe that increasing calcium intake, in the
form of non-dairy calcium supplementation, can prevent
gain of fat mass and loss of lean mass. The effect of cal-
cium supplementation in this population-based cohort is
consistent with the effect of dairy supplementation in
fat and lean mass changes in obese subjects with low
baseline calcium intake (< 600 mg/d) as reported by
Zemel et al. [18-20]. A similar significant finding is
reported for body weight in the WHI study in a free-liv-
ing population of 36282 postmenopausal women [22].
In our study, although we did not find significant dif-
ferences in the change of BMI among the three groups,
we did observe that changes in TrF, TrL, and PTrF are
significantly different between the calcium intervention
groups and the control group. This may be due to TrF
and TrL being more homogenous phenotypes and there-
fore more sensitive to the effect of calcium.
Figure 1 shows that in all three groups, subjects
tended to gain or maintain BMI in the first 2 years.
After that, they began to lose BMI in year 3 and 4. This
phenomenon is possibly age-related. In a similar study,
Caan et al. [22] observed age-related weight change.
Postmenopausal women (age ≥ 50) tend to gain and
peak their weight in mid to late sixties. Later in life they
begin to lose weight. In the present study, the mean
ages of the three groups at baseline were 65.2 ± 6.5
(SD), 66.0 ± 6.6 and 66.5 ± 7.5 years old in the placebo,
Ca-only, and Ca + D groups, respectively (Table 1). The
trajectory of BMI change in our cohort indicates that
age ~67 may be the turning point of the effect of age on
weight. Considering its potential effects, age was used as
a covariate to adjust all studied phenotypes.
The effect of age on BMI (weight) is consistent with
i t se f f e c to nT r L .F r o mF i g u r e1 ,i ti se v i d e n tt h a tt h e
subjects in all groups tend to increase TrL in the first
year and lose TrL thereafter. The consistent trajectory
of BMI and TrL indicates that the change of weight is
largely because of the change of TrL. This is compatible
with the fact that the main component of total body
weight is lean mass.
In contrast to TrL, TrF tends to increase with aging.
This phenomenon is consistent with other studies in
postmenopausal women [34,35]. Our data indicate that
higher calcium intake prevents the accumulation of TrF,
and helps to preserve TrL. Lean mass (mostly skeletal
muscle) is a key site for energy metabolism. These
effects collectively lead to the beneficial effect of redu-
cing the risk of obesity.
I nt h ep r e s e n ts t u d yc o h o r t ,m e a n±S Do fb a s e l i n e
calcium intake was 1016 ± 520 mg/d, and the baseline
calcium intake for nearly 31% of the subjects was over
1200 mg/d. This is similar to the WHI study (over 39%
subjects took over 1200 mg/d calcium). The mean ± SD
of baseline 25(OH)D in this study cohort was 73.2 ±
19.9 nmol/L, which is similar to other studies [36,37],
but higher than many other US cohorts [38,39].
The average (baseline to year 4) trial calcium supple-
ment was 826 ± 589 mg/d, which is higher than the
average dietary calcium (666 ± 323 mg/d) and average
habitual calcium supplement (342 ± 314 mg/d). At base-
line, habitual calcium supplementation was negatively
associated with BMI, TrF, TrL, and PTrF (P <0 . 0 1 ) .A t
the end of the study, trial calcium supplementation is
inversely correlated with ΔTrF and ΔPTrF, and posi-
tively correlated with ΔTrL. The levels achieved with
each type of calcium intake did not affect the correlation
analysis.
An interesting finding in this study is that at baseline
(Table 4), it is habitual calcium supplementation, not
the dietary calcium intake, that contributed to the
inverse correlation between BMI, TrF, TrL, PTrF and
total calcium intake. This result is similar to that of
Gonzalez, et al. [40], who reported an inverse correla-
tion between weight gain and calcium supplementation,
but not with dietary calcium intake. On the other hand,
others [18,41] have found that dietary calcium has more
of an effect on weight than does supplementation. One
reason for a lack of effect of dietary calcium is that self-
reported dietary calcium intake is difficult to measure.
Clinical trials measuring the effect of vitamin D sup-
plementation on obesity are few. Our study indicates
that vitamin D supplementation may have no additional
effect on body composition in the presence of high cal-
cium intake. This result is consistent with a previous
study conducted by Sneve, et al. [29], which reported
that high vitamin D supplementation does not lead to
weight loss.
At baseline, consistentw i t hp r e v i o u sr e p o r t s
[26,42,43], we observed that low serum 25(OH)D is
negatively associated with BMI, TrF, and TrL. At year 4,
Δ25(OH)D is inversely correlated with ΔBMI, ΔTrF and
ΔPTrF. These results indicate that serum 25(OH)D may
p l a yar o l ei no b e s i t y ,a l t h o u g ht h ec h a n g ei ns e r u m2 5
(OH)D does not linearly reflect the change in trial vita-
min D supplementation.
Our study shows that vitamin D supplementation and
serum 25(OH)D have different effects on obesity. The
different effects may be due to inter-individual differ-
ences in the effectiveness of the vitamin D supplementa-
tion. The increase of serum 25(OH)D in response to a
given dose of vitamin D supplementation is, as reported,
widely different from person to person [44]. We found
that, after a 12-month vitamin D intervention in our
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Page 7 of 9Ca + D group, among the 261 Ca + D subjects who
took > 80% vitamin D supplement dosage (i.e. > 880 IU/
d) and had serum 25(OH)D measurements at year 1
and baseline, 10 subjects decreased their serum 25(OH)
D levels on average by 7% [ie. Δ25(OH)D =-0.07]. More-
over, 251 subjects increased their serum 25(OH)D levels
on average by 42% [i.e. Δ25(OH)D = 0.42]. The average
vitamin D supplement for the 10 subjects was 1039 IU/
d, and for the 251 subjects was 1051 IU/d which was
only a little higher than 1039 IU/d.
One strength of this study is that the ethnic back-
grounds and living environments of these rural non-His-
panic white women are similar. Relative homogeneity of
the population in the parent study is likely to reduce the
influence of confounding factors on the measurement of
the calcium effect. In addition to the aforementioned
s t r e n g t h ,w ea r ea w a r eo fa ne x t a n tl i m i t a t i o ni nt h i s
study. Compared with some randomized controlled
trials specifically designed for obesity [18-20,22], one
limitation of the study is the lack of records of energy
intake and physical activity. However, these results are
still credible because the population was well-rando-
mized (no significant difference among groups for any
confounding factor).
Conclusion
In summary, study results show beneficial effects of high
calcium intake on obesity in a population-based study of
postmenopausal women who have a relatively high base-
line calcium intake. However, vitamin D supplementa-
tion may have no additional effect on body composition.
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